---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40597327.md"
description: "1. 2026–2027 adj. EBITDA margin target & GAAP profitability timeline?​2. Current LTV/CAC ratio & improvement plan amid competition?​3. Excess cash priority: buybacks, M&A, R&D or dividends? 2026 capital return plan?​4. Contingency plan if FDA restricts compounded GLP-1? Revenue exposure & shift speed?​5. Novo/Lilly branded GLP-1 supply timeline & terms? Any exclusive partnership?​6. Non-GLP-1 revenue % in 2026? Which vertical hits $1B+ by 2027?​7. Longevity/peptide launch timeline, pricing & 2026–2027 revenue contribution?​8. AI/lab services impact on retention/upsell? Lab user % & avg. upsell value by end-2026?​9. Mental health/chronic disease revenue timeline & key milestones?​10. 2026 international revenue target & profitability timeline?​11. Eucalyptus integration KPIs (AU/JP) & $100M quarterly contribution timeline?​12. Defensive moat vs. Amazon/Costco? How to avoid price competition?​13. Market share vs. Ro/LifeMD? 2026 trend reversal plan?​14. 2030 $6.5B revenue key assumptions (US/int’l, GLP-1/new verticals)?​15. 2026–2027 priority acquisition targets or strategic investment plans?"
datetime: "2026-05-09T10:14:01.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40597327.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40597327.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40597327.md)
author: "[MerlinXu](https://longbridge.com/en/profiles/14434751.md)"
---

# 1. 2026–2027 adj. EBITDA margin target & GAAP …


### Related Stocks

- [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md)
- [COST.US](https://longbridge.com/en/quote/COST.US.md)
- [LFMD.US](https://longbridge.com/en/quote/LFMD.US.md)
- [LFMDP.US](https://longbridge.com/en/quote/LFMDP.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)